CGAS and mature T-cell and NK-cell non-Hodgkin lymphoma: The cGAS‐STING pathway is closely associated with inflammation, a potential therapeutic target in inflammatory diseases,[41] and could predict distinct prognoses in patients with different tumors.[42, 43, 44] In our study, high cGAS‐STING pathway expression indicated a worse prognosis in patients with PTCL, which may further verify the prognostic value of inflammatory markers and partly unveil the underlying mechanism.